Synergy Pharmaceuticals (FRA:S90) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Synergy Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2018 was 0.00.

Synergy Pharmaceuticals's long-term debt to total assets ratio declined from Sep. 2017 (0.78) to Sep. 2018 (0.00). It may suggest that Synergy Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Synergy Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Synergy Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals LT-Debt-to-Total-Asset Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.93

1.31

0.25

0.70

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.78	0.70	0.88	1.22	-

Synergy Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Synergy Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (A: Dec. 2017 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2017 )	/	Total Assets (A: Dec. 2017 )
	=	97.988	/	140.782
	=	0.70

Synergy Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2018 is calculated as

LT Debt to Total Assets (Q: Sep. 2018 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2018 )	/	Total Assets (Q: Sep. 2018 )
	=	0	/	71.164
	=	0.00

Synergy Pharmaceuticals (FRA:S90) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Synergy Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines